(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
4 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 7.58%
@ $1.391
发出时间: 15 Feb 2024 @ 00:10
回报率: 2.08%
上一信号: Feb 14 - 04:52
上一信号:
回报率: 4.59 %
Live Chart Being Loaded With Signals
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies...
Stats | |
---|---|
今日成交量 | 591 541 |
平均成交量 | 960 072 |
市值 | 358.44M |
EPS | $0 ( 2024-03-19 ) |
下一个收益日期 | ( $-0.0900 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.64 |
ATR14 | $0.00600 (0.42%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-02 | Perez Jeffrey Thomas | Buy | 126 713 | Common Stock |
2024-05-02 | Kirk Randal J | Buy | 8 896 412 | Common Stock |
2024-05-02 | Kirk Randal J | Buy | 6 085 471 | Common Stock |
2024-05-02 | Kirk Randal J | Sell | 691 929 | Common Stock |
2024-04-05 | Thomasian Harry Jr. | Buy | 135 714 | Common Stock |
INSIDER POWER |
---|
67.22 |
Last 99 transactions |
Buy: 22 274 780 | Sell: 4 631 433 |
音量 相关性
Precigen Inc 相关性
10 最正相关 | |
---|---|
TATT | 0.813 |
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Precigen Inc 相关性 - 货币/商品
Precigen Inc 财务报表
Annual | 2023 |
营收: | $6.23M |
毛利润: | $-4.74M (-76.18 %) |
EPS: | $-0.390 |
FY | 2023 |
营收: | $6.23M |
毛利润: | $-4.74M (-76.18 %) |
EPS: | $-0.390 |
FY | 2022 |
营收: | $26.91M |
毛利润: | $20.57M (76.44 %) |
EPS: | $-0.400 |
FY | 2021 |
营收: | $103.87M |
毛利润: | $45.49M (43.79 %) |
EPS: | $-0.470 |
Financial Reports:
No articles found.
Precigen Inc
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。